Bridge Informatics

If TNS2026 showed us anything, it’s this: spatial biology isn’t about picking a winner, it’s about building a toolkit.

From Stereo-seq + MERFISH convergence to DISCO’s targeted isolation and Xenium customization, the field is maturing into something more practical: knowing which tool to use, and when.

That shift, from platform wars to methodological fluency, is what will actually move biology forward. Read more in today's blog: https://bridgeinformatics.com/meet-the-researchers-building-canadas-spatial-biology-toolkit/

Clinical trial terminations are rising, even as AI, bioinformatics, and predictive tools become more advanced.

A recent Nature Reviews Drug Discovery analysis found that sponsor-terminated phase II and III trials more than doubled from 11% in 2013 to 23% in 2023.

Why?

We spoke with Rich Harrison, Bridge Informatics board member and co-author of the study, about how stronger bioinformatics and biomarker-driven validation earlier in development could help teams enter the clinic with stronger evidence and lower risk.

The takeaway:
Better upstream validation, target biology, and patient stratification could significantly reduce costly late-stage failures.

Read the full blog to learn how bioinformatics can help de-risk clinical development earlier: https://bridgeinformatics.com/why-are-clinical-trial-terminations-increasing/